(Q50984412)

26 March 2018

title

Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. (English)

1 reference

26 March 2018

0 references

1 reference

2

1 reference

26 March 2018

Sindre Rolstad

10

1 reference

26 March 2018

Henrik Zetterberg

4

object named as

H Zetterberg

1 reference

26 March 2018

6

K Blennow

1 reference

26 March 2018

A Wallin

1

1 reference

26 March 2018

M Gustavsson

3

1 reference

26 March 2018

C Eckerström

5

1 reference

26 March 2018

A Edman

7

1 reference

26 March 2018

K Lind

8

1 reference

26 March 2018

A Nordlund

9

1 reference

26 March 2018

publication date

3 November 2011

1 reference

26 March 2018

Dementia and Geriatric Cognitive Disorders

published in

1 reference

26 March 2018

volume

32

1 reference

26 March 2018

issue

3

1 reference

26 March 2018

page(s)

193-197

1 reference

26 March 2018

Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine

cites work

1 reference

Outcome over seven years of healthy adults with and without subjective cognitive impairment

21 January 2018

1 reference

Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging

21 January 2018

1 reference

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

Subcortical ischaemic vascular dementia

21 January 2018

1 reference

Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia.

21 January 2018

1 reference

Subcortical vascular dementia biomarker pattern in mild cognitive impairment.

21 January 2018

1 reference

Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study

21 January 2018

1 reference

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

21 January 2018

1 reference

The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition

21 January 2018

1 reference

Stepwise comparative status analysis (STEP): a tool for identification of regional brain syndromes in dementia.

21 January 2018

1 reference

21 January 2018

1 reference

Bedside assessment of executive cognitive impairment: the executive interview

21 January 2018

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

21 January 2018

1 reference

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?

21 January 2018

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

21 January 2018

1 reference

No association between the α2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000333034

1 reference

26 March 2018

1 reference

26 March 2018